Skip to main content
Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc — Investor Relations & Filings

Ticker · CNTA ISIN · US1523091007 LEI · 213800GIDAARDSKOI827 US Manufacturing
Open in API
Filings indexed 548 across all filing types
Latest filing 2022-11-10 Earnings Release
Country GB United Kingdom
Listing US CNTA

About Centessa Pharmaceuticals plc

https://www.centessa.com/

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that utilizes a Research & Development innovation engine to discover and develop transformational medicines for patients. The company employs a data-driven approach to advance its portfolio of innovative assets. A key program in its pipeline is the development of potential best-in-class, orally administered orexin receptor 2 (OX2R) agonists for the treatment of sleep-wake disorders. Centessa's broader therapeutic focus often includes rare diseases and other areas with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 10, 2022, reporting the announcement of financial results for the quarter ended September 30, 2022. It includes a press release as an exhibit and explicitly states that the information is furnished and not filed, indicating it is an announcement rather than a full financial report. The document length is 3869 characters, which is relatively short and consistent with a current report or earnings release announcement. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to earnings releases or financial results announcements. Given the nature of the document as a current report announcing quarterly financial results, the appropriate classification is Earnings Release (ER).
2022-11-10 English
FORM 4
Director's Dealing
2022-11-03 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 13, 2022, reporting a departure of a director/officer (Chief Medical Officer) and appointment of another officer to assume those responsibilities. The key section is Item 5.02, which specifically addresses changes in directors or certain officers. There is no financial data or report content, only an announcement of management changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 4383 characters, which is short and consistent with a management change announcement rather than a full report.
2022-10-14 English
8-K Filing
Regulatory Filings
2022-10-06 English
FORM 4
Director's Dealing
2022-10-04 English
FORM 4
Director's Dealing
2022-10-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.